Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible for all
        • Our Story
          • Amneal at-a-glance
          • Our Founders
        • Our Purpose & Commitments
        • Our Culture
          • Learn, Lead, Succeed
          • Our Culture in Action
        • Our Milestones
        • Leadership
          • Executive Leadership
          • Board of Directors
        • Locations
        • Responsibility
          • Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Awards & Recognition
        • Amneal About
  • Products
        • Products We produce quality generic, specialty and biosimilar medicines
        • Our Portfolio
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
        • Amneal Products
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
        • Product Partnering
        • Amneal Research and Technology
  • Investors
        • Investors Become an Informed Investor
        • Amneal Investors
  • News
  • Careers
        • Careers Join our quest to make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
        • Amneal Careers
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 18, 2006
IMPAX Announces FDA Approval of Generic Wellbutrin XL 300 mg
Nov 22, 2006
IMPAX Announces Court of Appeals Remands Earlier Riluzole Patent Validity Decision Back to Lower Court
Nov 10, 2006
IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Ditropan(R) XL 15 mg
Nov 03, 2006
IMPAX Receives FDA Approval for Generic Versions of Urecholine(R) Tablets
Oct 26, 2006
IMPAX Receives FDA Approval for Generic Version of Colestid(R) Tablets
Oct 09, 2006
IMPAX Appoints Grant Thornton as Principal Accountant
Oct 03, 2006
IMPAX Announces Dismissal of Lawsuit Related to Generic Concerta(R)
Sep 07, 2006
IMPAX Prevails in Alza's Appeal Related to Generic Version of Ditropan(R) XL
Jul 11, 2006
IMPAX Announces the Launch of IMPAX Pharmaceuticals; Company's Branded Products Division
Jun 29, 2006
IMPAX Settles Solvay Litigation
May 03, 2006
IMPAX Receives FDA Approval for Generic Version of Colestid(R); Global Pharmaceuticals Division to Launch
Apr 07, 2006
IMPAX Comments on Wyeth's Lawsuit Related to Generic Versions of Effexor XR(R)
Apr 05, 2006
IMPAX Receives FDA Approval for Generic Version of SALAGEN(R) Tablets; Global Pharmaceuticals Division to Launch
Mar 07, 2006
IMPAX Receives FDA Non-Approvable Letter for Vadova; Company to Request Meeting With FDA
Jan 19, 2006
IMPAX Settles Patent Suit and Signs Marketing and Promotion Agreements with Shire
Jan 18, 2006
ADDERALL XR(R) - Litigation Update

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.49.0.3 (opens in new window)
Back to top